Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray

Abstract

Intercellular cell adhesion molecule-1 (ICAM-1), an important adhesion molecule in the immunoglobulin superfamily, is expressed on many cell types. Recent studies have identified ICAM-1 as a potential oncogene that promotes the development of epithelial ovarian cancer (EOC); it was also found to be associated with poor survival. However, the clinical significance of its expression in high-grade serous ovarian carcinoma (HGSOC) is unclear. Thus, this study aimed to investigate the significance of ICAM-1 expression in HGSOC. Data on ICAM1 expression and mutations in serous ovarian carcinoma (SOC) were obtained from the Cancer Genome Atlas (TCGA), and ICAM1 mRNA expression data in HGSOC were obtained from the Gene Expression Omnibus (GEO) database. ICAM-1 expression was evaluated by immunohistochemistry in HGSOC and normal fallopian tube tissues microarray. In TCGA data, amplification/mutation of ICAM1 was identified in 12% of serous ovarian carcinoma samples, and overexpression of ICAM1 mRNA predicted reduced overall survival in SOC. From TCGA and GEO data, SOC patients with ICAM1 mRNA overexpression treated with chemotherapeutic drugs that contained taxol or taxol and platin together had significantly reduced progression-free survival. According to GEO data, ICAM1 mRNA expression was found significantly higher in HGSOC than in control samples. In our study, ICAM-1 overexpression was observed in 63.1% (65/103) of HGSOCs. As a prognostic biomarker, overexpression of ICAM-1 predicted reduced recurrence-free and overall survival and is an independent risk factor for poor prognosis. These findings suggest that overexpression of ICAM-I is an independent indicator of poor prognosis for HGSOC and that it can serve as an effective clinical prognostic biomarker for this disease.

Identification of glutamyl-prolyl-tRNA synthetase as a new therapeutic target in hepatocellular carcinoma via a novel bioinformatic approach

“…ARS catalyzes amino acid and transfer RNA (tRNA) binding so that the mRNA sequence is accurately reflected in the protein amino acid sequence. In addition to catalysis, ARS proteins are also involved in inflammation, malignancy, immune system diseases, infections, cardiovascular disease, and nervous system diseases ( 30 , 31 ). Previous data showed that KRS is related to the development of gastric cancer (GC) lung cancer, and melanoma ( 32 ).…”

Mechanism of periplakin on ovarian cancer cell phenotype and its influence on prognosis

“…However, there are still few studies on the role of PPL in tumors, and its biological function is not yet clear. This study used public data from TCGA and GEO to conduct a bioinformatic analysis of the correlation between genes and disease ( 23 , 24 ). PPL expression in 31 malignant tumors and the relationship between PPL expression and patient prognosis were analyzed using TCGA.…”

MAPK10 Expression as a Prognostic Marker of the Immunosuppressive Tumor Microenvironment in Human Hepatocellular Carcinoma

“…Our study is however instrumental in providing a novel set of potentially important prognostic markers that may aid survival prognosis and therapy selection in the clinical treatment of HCC. Importantly, it had been reported that expressional levels of ICAM1 serve as a predictor of clinical outcome in several types of cancer including metastatic colorectal cancer (63), indolent non-Hodgkin lymphomas (64), high-grade serous ovarian carcinoma (65) and glioblastoma (66). Within inflamed tissue, ICAM1 was previously found to promote recruitment and survival of immunocytes such as eosinophils and T lymphocytes (67,68).…”